Cooperative Agreement U44CA221567

The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc. on September 19, 2024. The goal of this STTR project is to develop an RNA interference-based therapeutic to treat prostate cancer. The therapeutic, termed "NU002", will use lipopolyplex nanoparticles to deliver short interfering RNAs (siRNAs) derived from CAG trinucleotide repeat sequences....

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $636,289 to Duke University to conduct research aimed at developing a novel lipid nanoparticle (LNP) system for delivering the CRISPR/Cas13d gene editing technology to target the oncogenic transcription factor HOXB13 and inhibit prostate cancer metastasis. The key products and services to be delivered under this 5-year award include: Uncovering the molecular and genomic mechanisms by...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on developing innovative RNA nanoparticle and exosome-based technologies to silence the KRAS gene and inhibit metastatic colon cancer. The total award of $497,002 will support research at The Ohio State University, with sub-awards to the University of Houston and the University of Kentucky, to investigate mechanisms for delivering the CRISPR-dCas9-HDAC1 repressor complex and KRAS...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,999,972 to Transcode Therapeutics, Inc. to conduct Phase I clinical testing of a novel therapeutic agent called MN-anti-miR10b (commercially developed as TTX-MC138) that targets metastatic cancer cells. The therapy leverages Transcode's proprietary platform to selectively inhibit miRNA-10b, a validated driver of metastasis, in order to induce regression of metastatic lesions....

This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle formulation designed to improve the delivery and efficacy of combination chemotherapy for advanced pancreatic cancer. The key product being developed under this award is DUO-207, which combines a polymer-conjugated gemcitabine and paclitaxel in a single 14nm nanoparticle. This novel formulation...

The National Cancer Institute (NCI) awarded Creative Biotherapeutics LLC a $1.2M project grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The research aims to create a non-toxic therapeutic alternative that can increase overall survival and complete response rates for patients with recurrent, drug-resistant brain tumors and brain metastases. Key project objectives include designing inhibitors to...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to establish a targeted therapeutic microRNA (miRNA) delivery system using engineered cell-derived extracellular vesicles (EVs) to treat epidermal growth factor receptor (EGFR) cancers. The $351,517 award, spanning August 2024 to July 2029, will fund the development and validation of EV-based delivery of tumor suppressor miRNAs to EGFR-positive cancer...

This Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research program) to Senex Biotechnology Inc. aims to develop a nanoparticle formulation of a mediator kinase inhibitor drug for the treatment of peritoneal ovarian cancer metastases. The key goals are to optimize the nanoparticle formulation for improved intraperitoneal drug delivery, test its efficacy in peritoneal ovarian cancer models, and analyze its safety and pharmacokinetics. The...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...